Tetraphase Patent-Cliff Exposure & CMS Drug Spending Portfolio

Tetraphase (US): 1 reconciled FDA prescription therapies, $961K 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2037-01-01
2024 CMS Total Public Spend$961K
2024 Medicare Part D Spend$690K
2024 Medicaid Spend$271K
California HCAI SB 17 Filings6 WAC filings (max 27.9% 2-yr change)